Top 5 Companies To Watch In Right Now

Top 5 Companies To Watch In Right Now: NeurogesX Inc.(NGSX)

NeurogesX, Inc., a biopharmaceutical company, engages in developing and commercializing pain management therapies. The company offers Qutenza for the management of neuropathic pain associated with postherpetic neuralgia, and for the treatment of peripheral neuropathic pain in non-diabetic adults. It also develops NGX-1998, which has completed Phase 2 clinical study, is a topical liquid formulation of high concentration capsaicin to treat neuropathic pain conditions; and acetaminophen prodrugs that is in preclinical stage for use in acute pain, including traumatic pain, post-surgical pain, and fever. The company was formerly known as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX, Inc. was founded in 1998 and is headquartered in San Mateo, California.

Advisors' Opinion:

• [By CRWE]

  Today, NGSX remains (0.00%) +0.000 at $.0054 thus far (ref. google finance Delayed: 11:59AM EDT July 18, 2013).

  Acorda Therapeutics, Inc. previously reported it has acquired two neuropathic pain management assets from NeurogesX, Inc. (OTCBB: NGSX). Qutenza® is approved by the U.S. Food and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia. The Company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998.

• [By CRWE]

  Today, NGSX has shed (-6.67%) down -0.0005 at $.0070 with 29,206 shares in play thus far (ref. google finance Delayed: 10:44AM EDT July 17, 2013), but don't let this get you down.

  Acorda Therapeutics, Inc. previously reported it has acquired two neuropathic pain management assets from NeurogesX, Inc. (OTCBB: NGSX). Qutenza® is approved by the U.S. Food! and Drug Administration (FDA) for the management of neuropathic pain associated with postherpetic neuralgia. The Company also acquired NP-1998, a Phase 3 ready, prescription strength capsaicin topical solution, being assessed for the treatment of neuropathic pain. NP-1998 was previously referred to as NGX-1998.

source from Top Stocks Blog:http://www.topstocksblog.com/top-5-companies-to-watch-in-right-now.html